Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large drop in short interest in August. As of August 14th, there was short interest totaling 60,402 shares, a drop of 43.8% from the July 30th total of 107,470 shares. Based on an average trading volume of 43,727 shares, the short-interest ratio is currently 1.4 days. Currently, 2.0% of the company’s shares are sold short.

Exicure Stock Down 3.1%

NASDAQ:XCUR traded down $0.04 during trading hours on Tuesday, hitting $1.27. 1,189 shares of the company traded hands, compared to its average volume of 169,241. The company has a market cap of $8.32 million, a PE ratio of -0.96 and a beta of 3.65. The firm’s 50-day simple moving average is $1.67 and its 200-day simple moving average is $2.90. Exicure has a one year low of $1.05 and a one year high of $9.48.

Exicure (NASDAQ:XCUR) last announced its earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($18.60) by $18.42.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.